Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CATALYST: Amulet LAA Occluder vs NOAC in Atrial Fibrillation
NCT04226547Active, not recruiting
- Sponsor
- Abbott Laboratories
- Start
- Jul 2020
- Primary completion
- Jan 2029
- Countries
- 16
01
Overview
Randomised, open-label trial in Atrial fibrillation (AFib) (2 arms), sponsored by Abbott Laboratories. Primary endpoints: Composite of ischemic stroke, systemic embolism, or cardiovascular (CV) mortality at 2 years, Major bleeding or clinically relevant non-major bleeding (CRNMB) events, excluding procedure related events at 2 years and 1 more. Started Jul 2020; status: active, not recruiting.
02
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT04226547.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04226547.